Medical Science
| Open Access |
DOI: Changes In External Respiratory Function, Inflammatory Cytokines, And Brain Natriuretic Peptide Indicators In Chronic Obstructive Pulmonary Disease With Comorbid Ischemic Heart Disease
Nurullayev Bakhtiyor Azimboyevich , Assistant, Department of Internal Medicine in Family Medicine No. 2, Tashkent State Medical University, Tashkent, UzbekistanAbstract
Background: Chronic Obstructive Pulmonary Disease (COPD) and Ischemic Heart Disease (IHD) are leading causes of global morbidity and mortality, frequently coexisting as comorbid conditions. Their interplay creates a complex pathophysiological state that exacerbates the clinical course and worsens prognosis. The simultaneous assessment of pulmonary function, systemic inflammation, and cardiac strain in this comorbid population remains a critical area of investigation.
Objective: To study the changes in external respiratory function, the levels of key inflammatory cytokines (IL-6, TNF-α), and brain natriuretic peptide (NT-proBNP) in patients with COPD, particularly when it occurs in comorbidity with IHD.
Materials and Methods: A single-center, cross-sectional study was conducted at the Clinics of Tashkent State Medical University. A total of 120 male participants aged 45-70 years were enrolled and divided into three groups: Group 1 (n=40) - patients with COPD alone; Group 2 (n=40) - patients with IHD alone (stable angina, FC II); Group 3 (n=40) - patients with comorbid COPD and IHD. A control group (n=30) of healthy, age-matched individuals was also included. All participants underwent spirometry with bronchodilator testing. Serum levels of IL-6, TNF-α, and NT-proBNP were measured using enzyme-linked immunosorbent assay (ELISA).
Results: Patients with comorbid COPD and IHD (Group 3) demonstrated the most pronounced impairments in spirometric parameters (FEV1: 48.2±5.1% pred., FVC: 72.5±6.8% pred., FEV1/FVC: 52.8±4.9%) compared to other groups (p<0.001). These patients also exhibited a significant synergistic increase in inflammatory markers (IL-6: 8.45±1.32 pg/mL; TNF-α: 12.89±2.11 pg/mL) and NT-proBNP levels (485.6±75.4 pg/mL), which were substantially higher than in the groups with isolated diseases (p<0.001). Strong negative correlations were found between FEV1 and IL-6 (r = -0.78, p<0.01), FEV1 and NT-proBNP (r = -0.71, p<0.01), and a strong positive correlation between IL-6 and NT-proBNP (r = 0.82, p<0.01) in the comorbid group.
Conclusion: The comorbidity of COPD and IHD leads to a significant mutual aggravation of both conditions, characterized by severe obstructive ventilatory disorders, heightened systemic inflammation, and increased cardiac strain. The strong intercorrelations between these parameters suggest a shared pathophysiological pathway and highlight the need for an integrated diagnostic and therapeutic approach targeting both pulmonary and cardiovascular systems in this high-risk patient population.
Keywords
Chronic obstructive pulmonary disease, ischemic heart disease, comorbidity
References
GBD 2019 Diseases and Injuries Collaborators. Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020;396(10258):1204-1222.
Adeloye D, Song P, Zhu Y, et al. Global, regional, and national prevalence of, and risk factors for, chronic obstructive pulmonary disease (COPD) in 2019: a systematic review and modelling analysis. Lancet Respir Med. 2022;10(5):447-458.
Tsao CW, Aday AW, Almarzooq ZI, et al. Heart Disease and Stroke Statistics—2023 Update: A Report From the American Heart Association. Circulation. 2023;147(8):e93–e621.
Chen W, Thomas J, Sadatsafavi M, FitzGerald JM. Risk of cardiovascular comorbidity in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. Lancet Respir Med. 2015;3(8):631-639.
Sin DD, Man SF. Why are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular diseases? The potential role of systemic inflammation in chronic obstructive pulmonary disease. Circulation. 2003;107(11):1514-1519.
Agustí A, Hogg JC. Update on the Pathogenesis of Chronic Obstructive Pulmonary Disease. N Engl J Med. 2019;381(13):1248-1256.
Gan WQ, Man SF, Senthilselvan A, Sin DD. Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis. Thorax. 2004;59(7):574-580.
Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med. 2005;352(16):1685-1695.
Vonk-Noordegraaf A, Haddad F, Chin KM, et al. Right heart adaptation to pulmonary arterial hypertension: physiology and pathobiology. J Am Coll Cardiol. 2013;62(25 Suppl):D22-33.
Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease (2023 Report).
Barr RG, Bluemke DA, Ahmed FS, et al. Percent emphysema, airflow obstruction, and impaired left ventricular filling. N Engl J Med. 2010;362(3):217-227.
Januzzi JL Jr, van Kimmenade R, Lainchbury J, et al. NT-proBNP testing for diagnosis and short-term prognosis in acute destabilized heart failure: an international pooled analysis of 1256 patients: the International Collaborative of NT-proBNP Study. Eur Heart J. 2006;27(3):330-337.
Pavasini R, Tavazzi G, Biscaglia S, et al. Amino terminal pro brain natriuretic peptide predicts all-cause mortality in patients with chronic obstructive pulmonary disease: Systematic review and meta-analysis. Chron Respir Dis. 2017;14(2):117-126.
Rabe KF, Hurst JR, Suissa S. Cardiovascular disease and COPD: dangerous liaisons? Eur Respir Rev. 2018;27(149):180057.
Fabbri LM, Luppi F, Beghé B, Rabe KF. Complex chronic comorbidities of COPD. Eur Respir J. 2008;31(1):204-212.
Barnes PJ. Inflammatory mechanisms in patients with chronic obstructive pulmonary disease. J Allergy Clin Immunol. 2016;138(1):16-27.
Rutten FH, Moons KG, Cramer MJ, et al. Recognising heart failure in elderly patients with stable chronic obstructive pulmonary disease in primary care: cross sectional diagnostic study. BMJ. 2005;331(7529):1379.
Knuuti J, Wijns W, Saraste A, et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J. 2020;41(3):407-477.
Graham BL, Steenbruggen I, Miller MR, et al. Standardization of Spirometry 2019 Update. An Official American Thoracic Society and European Respiratory Society Technical Statement. Am J Respir Crit Care Med. 2019;200(8):e70-e88.
Watz H, Waschki B, Boehme C, et al. Extrapulmonary effects of chronic obstructive pulmonary disease on physical activity: a cross-sectional study. Am J Respir Crit Care Med. 2008;177(7):743-751.
Hawkins NM, Petrie MC, Jhund PS, Chalmers GW, Dunn FG, McMurray JJ. Heart failure and chronic obstructive pulmonary disease: diagnostic pitfalls and epidemiology. Eur J Heart Fail. 2009;11(2):130-139.
Barr RG. The epidemiology of vascular dysfunction relating to chronic obstructive pulmonary disease and emphysema. Proc Am Thorac Soc. 2011;8(6):522-527.
Mann DL. Inflammatory mediators and the failing heart: past, present, and the foreseeable future. Circ Res. 2002;91(11):988-998.
Calverley PM, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med. 2007;356(8):775-789.
Article Statistics
Copyright License
Copyright (c) 2025 Nurullayev Bakhtiyor Azimboyevich
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors retain the copyright of their manuscripts, and all Open Access articles are disseminated under the terms of the Creative Commons Attribution License 4.0 (CC-BY), which licenses unrestricted use, distribution, and reproduction in any medium, provided that the original work is appropriately cited. The use of general descriptive names, trade names, trademarks, and so forth in this publication, even if not specifically identified, does not imply that these names are not protected by the relevant laws and regulations.